Skip to content

Prevention of Oral Mucositis in Head and Neck Cancer.

Prevention of Oral Mucositis in Subjects Undergoing Radiotherapy for Head and Neck Cancer. A Randomized Clinical Trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05853692
Acronym
OMHNC-1
Enrollment
130
Registered
2023-05-11
Start date
2022-10-10
Completion date
2028-06-10
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Mucositis

Brief summary

Oral Mucositis (OM) consists in the painful inflammation and ulceration of the mucous membranes lining the digestive tract, lasting between 7 and 98 days; and starts as an acute inflammation of oral mucosa, tongue, and pharynx after RT exposure. Gel X spray is a product based on zinc gluconate. It could be helpful to achieve the prevention of Oral Mucositis and, in case of OM manifestation, the reduction of oral pain symptoms and to accelerate the healing process of oral mucositis ulcerations. The aim of this study is to demonstrate the efficacy of the treatment with Gel X to reduce the incidence of oral mucositis, in comparison with Sodium Bicarbonate.

Interventions

Three times a day (spray)

DEVICESodium Bicarbonate

Five times a day (rinse)

Sponsors

Catholic University of the Sacred Heart
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The principal investigator will be encharged of generating the allocation sequence, of enrolling the participants and of assigning the interventions to the participants. The coworkers who will evaluate the onset of OM and its severity will be blinded about the selected product.

Intervention model description

The study will be conducted as a single-blind randomized clinical trial (RCT). The population will be divided into two groups, receiving respectively the medical device and a solution based on Sodium Bicarbonate (5 g/L)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with diagnosis of the following HNC: oral cavity, pharynx, unknown primary, salivary glands, undergoing local radiotherapy for curative purpose * Patients with diagnosis of HNC: oral cavity, pharynx, unknown primary, salivary glands, undergoing local radiotherapy as an adjuvant to surgical resection * Patients able self-apply the product.

Exclusion criteria

* Patients with documented contraindication to any of the components of "Gel X" (there included eccipients): water, saccharin sodium, PVP, Taurine, Zinc Gluconate, PEG-40, Hydrogenated castor oil, Pullulan, Flavors * Patients with any neurological and psychiatric condition having an influence on the ability to self-apply the treatment * Patients participating to other clinical studies

Design outcomes

Primary

MeasureTime frameDescription
Oral MucositisOne week after the end of RadiotherapyYes/No

Secondary

MeasureTime frameDescription
Time of Oral Mucositis OnsetFrom Day 0 to 2 monthsDays
Severity of Oral MucositisOne week after the end of RadiotherapyDifference in Oral Mucositis Grade

Countries

Italy

Contacts

CONTACTCarlo Lajolo, Prof.
carlo.lajolo@unicatt.it+393401004585

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026